Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure
Precision BioSciences reported successful Phase 1 results for PBGENE-HBV, its hepatitis B treatment. The drug achieved undetectable pgRNA levels, reduced cccDNA, and showed a favorable safety profile at 0.4 mg/kg. The company plans to advance to a global Phase 2 study in 2027. Precision will host an investor webcast on November 9, 2026, to discuss the data.
How this was made
The 30-second read
Why it matters
The announcement provides fresh, material information likely to move PRNC stock as investors reassess the company's valuation.
Market read
First disclosure of pivotal trial data for a novel HBV cure platform, expected to affect PRNC price and biotech sector sentiment.
What to watch
Small patient cohort and limited safety data could temper enthusiasm; competition from other HBV cure approaches.
Background
Precision BioSciences announced late‑breaking Phase 1 data at the AASLD Liver Meeting, showing cccDNA reduction and manageable safety.
Market effects
May stimulate interest in gene‑editing biotech sector and HBV therapeutic pipeline.
US biotech investors likely respond; limited immediate global effect.
Highlights FDA Fast Track designations, could influence biotech valuations worldwide.
Counterpoint
Data set is early‑stage; efficacy in larger Phase 2 trials remains uncertain, risk of setbacks.
Key entities
- companyPrecision BioSciences
US‑listed biotech developing gene‑editing therapies for hepatitis B.
